FULL PDF
Abstract
Despite the vast heterogeneity of myelodysplastic neoplasm (MDS), treatment options are limited and an allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative approach. While, subsequently, allo-HSCT is the treatment of choice in fit high-risk MDS patients younger than 70 years, it should only be considered in young and fit low-risk MDS patients who suffer from severe and life threatening cytopenias, and fail all available conservative treatment options. With the increasing use of mismatched or haploidentical donors, the majority of MDS patients will have a suitable donor available, however, matched donors should still be preferred if rapidly available. Strategies to prevent relapse after allo-HSCT are scarce, and include the use of donor lymphocytes or the experimental use of hypomethylating agents in patients with impeding relapse detected by MRD or chimerism evaluation. Here, we summarize current treatment options and factors to consider in the context of allo-HSCT in MDS.
View more >>